Table 2.
Summary of the quantitative Aβ plaque size and burden analysis results.
| Plaque | Antibodies | DS | sAD | p-Value * |
|---|---|---|---|---|
| Cerebral Aβ burden in all cases (N = 10 cases, each) | ||||
| Size (range) |
6F/3D | 59.4 ± 13.3 (42.0–77.3) | 36.8 ± 12.7 (15.6–55.0) | <0.01 |
| Aβ42 | 83.2 ± 21.5 (38.4–111.4) | 50.6 ± 17.0 (28.2–75.5) | <0.01 | |
| AβNp3E | 97.5 ± 38.4 (46.1–173.2) | 57.1 ± 28.3 (25.5–124.8) | 0.02 | |
| Load (range) |
6F/3D | 7.6 ± 4.6 (1.8–16.2) | 4.7 ± 1.8 (2.1–8.2) | 0.22 |
| Aβ42 | 18.3 ± 6.7 (10.2–28.0) | 8.3 ± 2.6 (4.5–12.0) | <0.01 | |
| AβNp3E | 8.9 ± 4.8 (1.8–18.2) | 6.1 ± 2.0 (3.7–10.1) | 0.19 | |
| Cerebral Aβ burden in cases with Braak NFT stage VI (N = 8 and 6 cases, respectively) | ||||
| Size (range) |
6F/3D | 60.0 ± 13.8 (42.0–77.3) | 38.7 ± 10.2 (25.0–52.1) | 0.04 |
| Aβ42 | 78.1 ± 21.1 (38.4–111.4) | 49.3 ± 17.0 (28.2–75.5) | 0.03 | |
| AβNp3E | 105.7 ± 37.7 (56.8–173.2) | 52.3 ± 19.5 (25.5–84.0) | <0.01 | |
| Load (range) |
6F/3D | 9.0 ± 4.0 (4.4–16.2) | 5.8 ± 1.3 (4.3–8.2) | 0.18 |
| Aβ42 | 20.2 ± 6.2 (10.7–28.0) | 9.0 ± 2.6 (5.0–12.0) | <0.01 | |
| AβNp3E | 10.3 ± 4.2 (5.2–18.2) | 7.0 ± 2.1 (3.7–10.1) | 0.18 | |
| Cerebellar molecular layer Aβ burden (N = 10 and 7 cases, respectively) | ||||
| Load (range) |
6F/3D | 2.0 ± 1.6 (0.2–5.1) | 0.9 ± 0.8 (0.1–3.4) | 0.16 |
| Aβ42 | 35.3 ± 11.8 (20.7–55.6) | 8.7 ± 8.4 (1.6–28.4) | <0.01 | |
| AβNp3E | 4.9 ± 2.2 (2.0–8.2) | 2.2 ± 1.3 (0.1–5.5) | 0.06 | |
Boldface signifies values that are significant at p < 0.05. * Comparison between the DS and sAD groups using Mann–Whitney U test.